MEDVi vs Remedy Meds: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only Remedy Meds prints a comparable month-to-month price, $399 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only Remedy Meds prints a comparable month-to-month price, $299 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
MEDVi and Remedy Meds, measure by measure
| Measure | MEDVi | Remedy Meds |
|---|---|---|
| Tirzepatide, month to month | — | $399 (per 28-day cycle) |
| Tirzepatide, lowest printed | — | $399 (4-week supply; $279 first month only) |
| Semaglutide, month to month | — | $299 (per 28-day cycle) |
| Semaglutide, lowest printed | — | $299 (4-week supply; $179 first month only) |
| Dose pricing | not confirmed | same price at every dose |
| Membership or program fee | not confirmed | none |
| Computed score | 0 of 40 (position 21 of 27) | 24.3 of 40 (position 7 of 27) |
| FDA warning letters | 721455 (2026-02-20) | 716830 (2025-09-09) |
| November 20 read | not readable Nov 20 | first-party read |
Strengths and limitations: which fits whom
MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. Remedy Meds prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Remedy Meds | tirzepatide | — | $399 |
| Remedy Meds | semaglutide | — | $299 |
Regulatory record
FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 716830 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Remedy Meds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, MEDVi or Remedy Meds?
On compounded tirzepatide, only Remedy Meds prints a comparable month-to-month price, $399 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible. On compounded semaglutide, only Remedy Meds prints a comparable month-to-month price, $299 per 28-day cycle; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Do MEDVi and Remedy Meds charge a membership fee?
MEDVi: not confirmed on November 20, 2026; Remedy Meds: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are MEDVi and Remedy Meds medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- Remedy Meds pricing page (read November 20, 2026)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03)
- FDA warning letter 716830 to Remedy Meds (dated 2025-09-09, posted 2025-09-16)